The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
Securities Code: 301207
Securities Abbreviation: Hualan Vaccine
Announcement No.: 2026-005
Announcement on the Continued Use of Part of the Idle Raised Funds for Cash Management
Hualan Biological Vaccine Co., Ltd. (hereinafter referred to as "the Company" or "Hualan Vaccine") held the 18th meeting of the second board of directors on February 27, 2026, where it reviewed and approved the proposal on the continued use of part of the idle raised funds for cash management. It was agreed to continue using no more than RMB 1 billion of idle raised funds for cash management, ensuring that it does not affect the construction of the investment projects (hereinafter referred to as "Investment Projects") and the normal production and operation of the Company. The cash management will be effective for 12 months from the date of the board's approval. Within the above limit and period, the funds can be used in a rolling manner. The specific situation is announced as follows:
1. Basic Situation of Raised Funds
According to the approval from the China Securities Regulatory Commission on the initial public offering of Hualan Biological Vaccine Co., Ltd. (Zheng Jian Xu Ke [2022] No. 2), the Company was authorized to publicly issue 40,010,000 shares of RMB ordinary shares (A shares), with a par value of RMB 1 per share, at an issue price of RMB 56.88 per share, raising a total of RMB 2,275,768,800.00. After deducting various issuance expenses of RMB 31,565,696.07 (including tax), the actual net raised funds amounted to RMB 2,244,203,103.93. The raised funds were transferred to the Company's designated account on February 14, 2022. The Company signed a tripartite supervision agreement for the special account for raised funds with the sponsor and the bank holding the raised funds to jointly supervise the use of the raised funds. Dahua Certified Public Accountants (Special General Partnership) conducted an examination of the raised funds and issued the verification report No. Dahua Yan Zi [2022] 000066.
2. Use of Raised Funds
According to the fundraising plan disclosed in the Company's prospectus for the initial public offering and listing on the Growth Enterprise Market (hereinafter referred to as "the Prospectus"), combined with the actual net amount of raised funds, the current investment projects and the use plan of raised funds are as follows:
| No. | Project | Total Committed Investment Amount | Adjusted Investment Amount |
|---|---|---|---|
| 1 | Influenza Vaccine Development and Industrialization and Existing Product Supply Assurance Project (completed) | 108,426.42 | 80,107.90 |
| 2 | Development and Industrialization of Freeze-Dried Human Rabies Vaccine Project | 8,600.00 | 7,735.45 |
| 3 | Development and Industrialization of Multivalent Bacterial Vaccine Project | 27,425.00 | 24,667.97 |
| 4 | Development and Industrialization of New Pneumonia Vaccine Project (before change) | 76,080.81 | 33,901.04 |
| 5 | New Vaccine R&D Platform Construction Project | 28,970.51 | 26,058.11 |
| 6 | Development and Industrialization of Recombinant Shingles Vaccine Project (after change) | — | 56,421.08 |
| Total | 249,502.74 | 228,891.55 |